ISRAEL JOHN THUISSARD VASALLO-rekin lankidetzan egindako argitalpenak (7)

2022

  1. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 59

  2. Patients' self-assessment of essential tremor severity by a validated scale: A useful tool in telemedicine?

    Parkinsonism and Related Disorders, Vol. 96, pp. 22-28

  3. Risk and prognostic factors for SARS-CoV-2 infection in Spanish population with multiple sclerosis during the first five waves

    Frontiers in Neurology, Vol. 13

2020

  1. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study

    CNS Drugs, Vol. 34, Núm. 12, pp. 1275-1286

  2. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population

    Journal of Neurology, Vol. 267, Núm. 8, pp. 2362-2371

2018

  1. Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis

    Journal of Neurology, Vol. 265, Núm. 10, pp. 2182-2189

2016

  1. Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort JC virus seroprevalence in Spain

    Journal of the Neurological Sciences, Vol. 365, pp. 16-21